CD40-activated B cells contribute to mesothelioma tumor regression

Immunology and Cell Biology

Volumn 89, Issue 2, 2011, Pages 255-267

  Jackaman, Connie ^a   Cornwall, Scott ^b,c   Graham, Peter Thomas ^b,c   Nelson, Delia Jane ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

agonist anti CD40 antibody; B cells; cytotoxic T cells; tumor immunity; tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIGEN; CD40 ANTIGEN; FGK 45; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER CELL; CANCER INHIBITION; CANCER REGRESSION; CELL ISOLATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MESOTHELIOMA; MOUSE; NONHUMAN; SPLEEN; SURVIVAL TIME;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN PRESENTATION; ANTIGENS, CD40; ANTIGENS, NEOPLASM; AUTOANTIGENS; B-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHOCYTE ACTIVATION; MESOTHELIOMA; MICE; REMISSION INDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

MUS;

EID: 79951942585     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.88     Document Type: Article

References (53)

1. Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 1998; 10: 443-448. (Pubitemid 28564373)
2. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002; 99: 5561-5566. (Pubitemid 34411588)
3. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004; 173: 5923-5928. (Pubitemid 39487745)
4. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63: 4490-4496. (Pubitemid 36951021)
5. Hamzah J, Nelson D, Moldenhauer G, Arnold B, Hammerling GJ, Ganss R. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest 2008; 118: 1691-1699. (Pubitemid 351632373)
6. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT et al. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008; 20: 1467-1479.
7. Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007; 13: 354-360. (Pubitemid 46376686)
8. Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG et al. CD40 ligation for immunotherapy of solid tumours. J Immunol Methods 2001; 248: 139-147. (Pubitemid 32167031)
9. Davidson JA, Musk AW, Wood BR, Morey S, Ilton M, Yu LL et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother 1998; 21: 389-398. (Pubitemid 28452093)
10. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BW, Scott B. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin- 12. Am J Respir Cell Mol Biol 1999; 21: 347-356. (Pubitemid 129517189)
11. van Bruggen I, Nelson DJ, Currie AJ, Jackaman C, Robinson BW. Intratumoral poly-Nacetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model. J Immunother 2005; 28: 359-367. (Pubitemid 40962329)
12. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003; 171: 5051-5063. (Pubitemid 37432786)
13. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000; 7: 663-670. (Pubitemid 30314050)
14. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998; 21: 211-217. (Pubitemid 28222279)
15. Nelson DJ, Robinson BW, Allan J, van der Most R. Gene therapy of mesothelioma. Expert Opin Biol Ther 2005; 5: 1039-1049. (Pubitemid 41170034)
16. Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP et al. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40T antigen transgenic mice. J Immunol 2003; 171: 697-707.
17. Banchereau J, Briere F, Liu YJ, Rousset F. Molecular control of B lymphocyte growth and differentiation. Stem Cells 1994; 12: 278-288. (Pubitemid 24156070)
18. Lee BO, Moyron-Quiroz J, Rangel-Moreno J, Kusser KL, Hartson L, Sprague F et al. CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses. J Immunol 2003; 171: 5707-5717. (Pubitemid 37467185)
19. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004; 103: 2046-2054. (Pubitemid 38326219)
20. Kim SK, Nguyen Pham TN, Nguyen Hoang TM, Kang HK, Jin CJ, Nam JH et al. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol 2009; 88: 1113-1123.
21. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003; 63: 2836-2843. (Pubitemid 36667155)
22. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999; 93: 1992-2002. (Pubitemid 29128502)
23. Kondo E, Gryschok L, Schultze JL, von Bergwelt-Baildon MS. Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J Immunother 2009; 32: 157-160.
24. Canevari S, Pupa SM, Menard S. 1975-1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol 1996; 7: 227-232.
25. Robinson C, Callow M, Stevenson S, Scott B, Robinson BW, Lake RA. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol 2000; 22: 550-556. (Pubitemid 30319541)
26. Houghton AN, Uchi H, Wolchok JD. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell 2005; 7: 403-405. (Pubitemid 40719122)
27. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007; 19: 209-216. (Pubitemid 46356960)
28. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7: 411-423. (Pubitemid 40719125)
29. Schreiber H, Wu TH, Nachman J, Rowley DA. Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol 2000; 10: 351-357.
30. Manson LA. Anti-tumor immune responses of the tumor-bearing host: the case for antibody-mediated immunologic enhancement. Clin Immunol Immunopathol 1994; 72: 1-8. (Pubitemid 24227329)
31. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4: 627-630. (Pubitemid 28237366)
32. Brodt P, Gordon J. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 1978; 121: 359-362.
33. Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May Jr KF, Feng L et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 2000; 48: 541-549.
34. Monach PA, Schreiber H, Rowley DA. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 1993; 55: 1356-1361.
35. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005; 117: 574-586. (Pubitemid 41504545)
36. Gordon J, Holden HT, Segal S, Feldman M. Anti-tumor immunity in B-lymphocyte-deprived mice. III. Immunity to primary Moloney sarcoma virus-induced tumors. Int J Cancer 1982; 29: 351-357. (Pubitemid 12141242)
37. Schultz KR, Klarnet JP, Gieni RS, HayGlass KT, Greenberg PD. The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science 1990; 249: 921-923.
38. + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010; 184: 4006-4016.
39. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999; 162: 5838-5845. (Pubitemid 29314936)
40. Zhang XK, Moussa O, LaRue A, Bradshaw S, Molano I, Spyropoulos DD et al. The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice. J Immunol 2008; 181: 1644-1654.
41. Hardy RR. B-1 B cell development. J Immunol 2006; 177: 2749-2754. (Pubitemid 44277787)
42. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-483.
43. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5: 774-779. (Pubitemid 29318611)
44. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001; 2: 1103-1108. (Pubitemid 33130143)
45. Fang W, Nath KA, Mackey MF, Noelle RJ, Mueller DL, Behrens TW. CD40 inhibits B cell apoptosis by upregulating bcl-xL expression and blocking oxidant accumulation. Am J Physiol 1997; 272: C950-C956.
46. Mackus WJ, Lens SM, Medema RH, Kwakkenbos MJ, Evers LM, Oers MH et al. Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation. Int Immunol 2002; 14: 973-982.
47. Erickson LD, Vogel LA, Cascalho M, Wong J, Wabl M, Durell BG et al. B cell immunopoiesis: visualizing the impact of CD40 engagement on the course of T cell-independent immune responses in an Ig transgenic system. Eur J Immunol 2000; 30: 3121-3131.
48. Erickson LD, Durell BG, Vogel LA, O'Connor BP, Cascalho M, Yasui T et al. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest 2002; 109: 613-620. (Pubitemid 34204840)
49. Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 2003; 107: 976-983. (Pubitemid 37429840)
50. Jackaman C, Cornwall S, Lew AM, Zhan Y, Robinson BW, Nelson DJ. Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur Respir J 2009; 34: 162-175.
51. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991; 350: 423-426. (Pubitemid 21912244)
52. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 1963; 17: 299-313.
53. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994; 171: 131-137. (Pubitemid 24140219)